Suggestions for thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19

Casini Alessandro\textsuperscript{a}, Alberio Lorenzo\textsuperscript{b}, Angelillo-Scherrer Anne\textsuperscript{c}, Fontana Pierre\textsuperscript{d}, Gerber Bernhard\textsuperscript{d}, Graf Lukas\textsuperscript{e}, Hegemann Inga\textsuperscript{f}, Korte Wolfgang\textsuperscript{g}, Kremer Hovinga Johanna A.\textsuperscript{h}, Lecompte Thomas\textsuperscript{i}, Martinez Maria\textsuperscript{i}, Nagler Michael\textsuperscript{i}, Studt Jan-Dirk\textsuperscript{i}, Tsakiris Dimitrios\textsuperscript{b}, Wuillemin Walter\textsuperscript{i}, Asmis Lars M.\textsuperscript{i}, Working Party on Hemostasis of the Swiss Society of Hematology

Growing evidence from multiple retrospective cohorts indicates that hospitalised COVID-19 patients often could suffer from an excessive coagulation activation leading to an increased risk of venous and arterial thrombosis (including small calibre vessels) and a poor clinical course [1]. Notably, D-dimer level at the time of hospital admission is a predictor of the risk of development of acute respiratory distress syndrome (ARDS) [2], the risk of intensive care admission and the risk of death [3]. An observational study among COVID-19 patients with elevated D-dimer levels at baseline showed that the 28-day mortality was lower in those receiving heparin than in those who did not [4].

Based on the available literature and published recommendations from the International Society of Thrombosis and Hemostasis (https://www.isth.org/), from the American Society of Hematology (https://www.hematology.org/covid-19) and from the Society for Thrombosis and Haemostasis Research (http://gth-online.org), the Working Party on Hemostasis (Swiss Society of Hematology) proposes the following recommendations for pharmacological thromboprophylaxis in COVID-19 patients in the acute setting. Suggestions will be regularly updated:

- All in-hospital COVID-19 patients should receive pharmacological thromboprophylaxis according to a risk stratification score, unless contraindicated.
- In patients with creatinine clearance $\geq$30 ml/min, low molecular weight heparin (LMWH) should be administered according to the prescribing information. An increased dose should be considered in overweight patients (>100 kg).
- In patients with creatinine clearance <30 ml/min, unfractionated heparin (UFH) subcutaneously twice or three times daily or intravenously should be administered according to the prescribing information. An increased dose should be considered in overweight patients (>100 kg).
  - Anti-Xa activity should be monitored when indicated (e.g., evidence of renal dysfunction).
  - Antithrombin need not be monitored but this could be considered on an individual basis in cases of disseminated intravascular coagulation or sepsis-induced coagulopathy or heparin resistance.
  - We suggest regularly monitoring prothrombin time, D-dimers, fibrinogen, the platelet count, lactate dehydrogenase (LDH), creatinine and alanine aminotransferase (ALT) (daily or at least 2-3 times per week).
  - In patients in intensive care with a large increase in D-dimers, severe inflammation, or signs of hepatic or renal dysfunction or imminent respiratory failure, intermediate or therapeutic dosing of LMWH or UFH should be considered, according to the bleeding risk.
  - Heparin-induced thrombocytopenia (HIT) should be considered in patients with fluctuations in platelet counts or signs of heparin resistance.
  - In patients undergoing extracorporeal membrane oxygenation (ECMO) treatment we suggest maintaining UFH at doses bringing anti-Xa activity into the therapeutic range.
  - There are no data on the use of direct oral anticoagulants.

**Disclosure statement**
No financial support and no other potential conflict of interest relevant to this article was reported.
References


